AbbVie Inc. (ABBV) Stock
NYSEABBV has an Alpha Score of 57 out of 100 (moderate), computed on Oct 28, 2026 from 3 of 4 sub-scores. 50 members of Congress disclosed 142 trades in ABBV since 2013: 74 purchases and 67 sales, most recently Pete Sessions (sale, Sep 14, 2026). 6 of the hedge funds AlphaScala tracks reported ABBV in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $797.64M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 81.0 and its net margin 9.8% (key statistics as of Oct 22, 2026).
What is ABBV's Alpha Score?
How it works →Alpha Score of 57 reflects moderate overall profile with strong momentum, weak value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 28, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded AbbVie Inc. (ABBV)?
Most recent: Pete Sessions (sale, Sep 14, 2026); records start Jan 1, 2013.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Pete Sessions R-TX · House | 2026-09-14 | sale | $15k – $50k |
| Josh Gottheimer D-NJ · House | 2026-05-05 | sale | $1k – $15k |
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $15k – $50k |
| Julie Johnson D-TX · House | 2025-12-18 | sale | $1k – $15k |
| Julia Letlow R-LA · House | 2025-12-08 | sale | $1k – $15k |
| Julie Johnson D-TX · House | 2025-11-13 | partial sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-31 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded ABBV, with filing lags →Which hedge funds own ABBV?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 3.17M | $797.64M | +547% |
| Marshall Wace | 2.99M | $752.53M | +281758% |
| D.E. Shaw David Shaw | 2.10M | $529.03M | +212% |
| Millennium Management Israel Englander | 1.52M | $381.61M | +124% |
| Point72 Steve Cohen | 367K | $92.31M | NEW |
| Bridgewater Associates Ray Dalio | 12K | $2.96M | -61% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are AbbVie Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 14, 26 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | SELL | 32.7K | $8.2M |
| Mar 4, 26 | Purdue David Ryan | SVP, Controller | SELL | 5.2K | $1.2M |
| Mar 2, 26 | Siatis Perry C | EVP, GC AND SECRETARY | SELL | 5.8K | $1.3M |
| Mar 2, 26 | Siatis Perry C | EVP, GC AND SECRETARY | SELL | 10.3K | $2.4M |
| Mar 2, 26 | Siatis Perry C | EVP, GC AND SECRETARY | SELL | 2.6K | $612K |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are ABBV's key statistics?
Key statistics as of Oct 22, 2026
How does ABBV's valuation compare with the Healthcare sector?
| Metric | ABBV | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 81.0 | 27.1 | 97 |
| Net margin | 9.80% | 5.48% | 139 |
| Return on equity | 95.59% | 6.84% | 158 |
| Dividend yield (payers) | 4.47% | 1.62% | 50 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
What did AbbVie Inc.'s latest SEC filings say?
Latest 4AbbVie Updates 2026 Earnings Guidance Following First Quarter Acquired IPR&D and Milestones Expense
AbbVie Inc. filed an 8-K on April 3, 2026, to provide an update on its financial expectations for the first quarter and full year of 2026. The company reported that it expects to incur $744 million in pre-tax acquired In-Process Research and Development (IPR&D) and milestone expenses during the first quarter. This expense represents an unfavorable impact of $0.41 per share on both GAAP and adjusted non-GAAP diluted earnings per share. The company noted that these results for the quarter ended March 31, 2026, are preliminary and subject to final closing procedures. While AbbVie does not typically forecast IPR&D and milestone expenses due to the uncertainty regarding the timing and occurrence of such transactions, the company has updated its guidance to incorporate this specific first-quarter impact. Consequently, AbbVie revised its full-year 2026 adjusted diluted earnings per share guidance to a range of $13.96 to $14.16. Additionally, the company provided a first-quarter 2026 adjusted diluted earnings per share guidance range of $2.56 to $2.60. The filing includes a cautionary note regarding forward-looking statements, citing risks such as intellectual property challenges, competition, research and development difficulties, and macroeconomic factors.
- ›Reported $744 million in pre-tax acquired IPR&D and milestone expenses for Q1 2026.
- ›Adjusted Q1 2026 diluted EPS guidance to a range of $2.56 to $2.60.
- ›Updated full-year 2026 adjusted diluted EPS guidance to $13.96 to $14.16.
- ›Confirmed the $0.41 per share negative impact of IPR&D expenses on both GAAP and non-GAAP earnings.
AbbVie Completes Public Offering of Senior Notes Across Seven Different Maturity Tranches
On March 4, 2026, AbbVie Inc. finalized an underwritten public offering of senior notes totaling several billion dollars in aggregate principal amount. The offering consists of seven distinct series of notes, including floating rate notes due 2028 and fixed-rate notes with maturities ranging from 2028 to 2066. The fixed-rate notes carry coupon rates between 3.775% and 5.650%. These securities are unsecured, unsubordinated obligations of the company and rank equally with existing unsecured debt. The notes were issued under a base indenture dated November 8, 2012, as supplemented by a supplemental indenture dated March 4, 2026. The company retains the right to optionally redeem the notes, subject to specific make-whole provisions or par call dates depending on the series. The offering was conducted pursuant to a registration statement filed in February 2025.
- ›Completed public offering of seven series of senior notes.
- ›Issued $750 million in floating rate notes due 2028.
- ›Issued fixed-rate notes with maturities in 2028, 2031, 2033, 2036, 2056, and 2066.
- ›Established optional redemption terms including make-whole provisions and par call dates.
- ›Executed Supplemental Indenture No. 12 to govern the new debt obligations.
AbbVie Announces Public Offering of Senior Notes Totaling Approximately Eight Billion Dollars
On February 24, 2026, AbbVie Inc. entered into an underwriting agreement to issue and sell $8 billion in aggregate principal amount of senior notes. The offering includes seven series of notes with varying maturities ranging from 2028 to 2066, including floating rate notes and fixed-rate notes with coupons between 3.775% and 5.650%. The company expects to receive approximately $7.95 billion in net proceeds from the offering after deducting underwriting discounts and estimated expenses. AbbVie intends to use these proceeds primarily to repay $2.0 billion currently outstanding under its 364-day delayed draw term loan facility maturing in May 2026. Remaining funds are designated for general corporate purposes, which may include the repayment or repurchase of other outstanding debt. The offering is expected to close on March 4, 2026, subject to customary closing conditions. The notes were issued under an existing shelf registration statement.
- ›Issuance of $8 billion in aggregate principal amount of senior notes.
- ›Seven series of notes issued with maturities ranging from 2028 to 2066.
- ›Net proceeds of approximately $7.95 billion expected from the offering.
- ›Primary use of proceeds is to repay $2.0 billion in outstanding term loan debt.
- ›Closing of the note offering expected on March 4, 2026.
AbbVie 10-K Filing Details Strategic Acquisitions and Long-Term Debt Maturity Schedule
AbbVie Inc. filed its 2025 10-K, outlining its financial position and ongoing corporate development activities. The filing highlights a series of strategic acquisitions and collaborations aimed at expanding the company's pipeline. Key transactions include the acquisition of Cerevel Therapeutics in August 2024 and ImmunoGen in February 2024. Additionally, the company entered into various collaborative arrangements throughout 2025, including partnerships with Gilgamesh Pharmaceuticals, Ichnos Glenmark Innovation, Capstan Therapeutics, ADARx Pharmaceuticals, and Gubra AS. The company continues to manage a complex capital structure involving numerous senior notes and term loans with varying maturity dates extending through 2055. The filing also notes ongoing restructuring plans, including the finalization of the Allergan integration and other internal efficiency initiatives. The company maintains significant investments in developed technology rights and licensing agreements, which are subject to amortization and periodic impairment assessments. The financial data provided reflects the company's commitment to maintaining liquidity while funding research and development through both internal efforts and external business development.
- ›Acquired Cerevel Therapeutics in August 2024 to bolster neuroscience pipeline.
- ›Completed acquisition of ImmunoGen in February 2024 to expand oncology portfolio.
- ›Entered into multiple new collaborative research and development agreements during 2025.
- ›Maintained extensive long-term debt portfolio with maturities ranging from 2026 to 2055.
- ›Continued execution of restructuring plans including the legacy Allergan integration.
- ›Reported ongoing investments in developed technology rights and licensing arrangements.
ABBV price chart
Powered by TradingViewWhat does AbbVie Inc. do?
AbbVie Inc. is a research-based biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative medicines and therapies worldwide. Headquartered in North Chicago, Illinois, and founded in 2012 as a spin-off from Abbott Laboratories, it employs approximately 55,000 people and operates primarily in the pharmaceuticals and biotechnology sector. Key products include Humira, a leading treatment for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis; Skyrizi and Rinvoq for immunology indications like plaque psoriasis and ulcerative colitis; Imbruvica for blood cancers; and Botox for neurological conditions and aesthetics following the 2020 Allergan acquisition. AbbVie Inc. maintains a robust pipeline addressing immunology, oncology, neuroscience, and other therapeutic areas, with recent advancements in treatments for essential tremor and kidney disease. Its global presence underscores its significant role in advancing healthcare solutions and contributing to the biopharmaceutical industry's growth.